{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:58Z","timestamp":1792782718808,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital Medical University-Yingkang Life Science and Innovation Elite Plan project","award":["2024KCJY0102"],"award-info":[{"award-number":["2024KCJY0102"]}],"id":[{"id":"https:\/\/ror.org\/013xs5b60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"2.\tBeijing Natural Science Foundation-Haidian Original Innovation Joint Fund Project","award":["L222022"],"award-info":[{"award-number":["L222022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07216-5","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:55:09Z","timestamp":1785347709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary central nervous system lymphoma in the molecular era: genomic drivers, liquid biopsy, and targeted therapeutic strategies"],"prefix":"10.1007","volume":"105","author":[{"given":"Feng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongrui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"1","key":"7216_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9(1):29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"7216_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"7","key":"7216_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"6","key":"7216_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1055\/s-0043-1776783","volume":"43","author":"T Shah","year":"2023","unstructured":"Shah T, Venur VA (2023) Central nervous system lymphoma. Semin Neurol 43(6):825\u2013832. https:\/\/doi.org\/10.1055\/s-0043-1776783","journal-title":"Semin Neurol"},{"issue":"21","key":"7216_CR5","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35(21):2410\u20132418. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"7216_CR6","doi-asserted-by":"publisher","first-page":"175628641879356","DOI":"10.1177\/1756286418793562","volume":"11","author":"S Low","year":"2018","unstructured":"Low S, Han CH, Batchelor TT (2018) Primary central nervous system lymphoma. Ther Adv Neurol Disord 11:1756286418793562. https:\/\/doi.org\/10.1177\/1756286418793562","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"7216_CR7","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, SonderskovGorlov J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4(11):e510\u2013e523. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"issue":"32","key":"7216_CR8","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molucon-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C, Lymphoma LOCNfC (2022) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol 40(32):3692\u20133698. https:\/\/doi.org\/10.1200\/JCO.22.00491","journal-title":"J Clin Oncol"},{"issue":"10","key":"7216_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Molucon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C, Intergroupe G-A, the LOCNfCNSL (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37(10):823\u2013833. https:\/\/doi.org\/10.1200\/JCO.18.00306","journal-title":"J Clin Oncol"},{"issue":"7","key":"7216_CR10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosee P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gorlov JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G, IELSG32 study investigators (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36(7):1870\u20131878. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"issue":"2","key":"7216_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/neuonc\/noaf221","volume":"28","author":"A Omuro","year":"2026","unstructured":"Omuro A, DeAngelis LM, Polley MC, Correa D, Wefel JS, Bovi JA, Rosenblum M, Corn BW, Aneja S, Grommes C, Peereboom DM, Lallana EC, Werner-Wasik M, Rogers CL, Iwamoto FM, Yu HM, Donnelly ED, Struve TD, Won M, Mehta MP (2026) Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro Oncol 28(2):371\u2013382. https:\/\/doi.org\/10.1093\/neuonc\/noaf221","journal-title":"Neuro Oncol"},{"issue":"1","key":"7216_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","volume":"25","author":"K Hoang-Xuan","year":"2023","unstructured":"Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Ruda R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC (2023) European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol 25(1):37\u201353. https:\/\/doi.org\/10.1093\/neuonc\/noac196","journal-title":"Neuro Oncol"},{"issue":"7","key":"7216_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/neuonc\/noad038","volume":"25","author":"M Weller","year":"2023","unstructured":"Weller M, Le Rhun E, Van den Bent M, Chang SM, Cloughesy TF, Goldbrunner R, Hong YK, Jalali R, Jenkinson MD, Minniti G, Nagane M, Razis E, Roth P, Ruda R, Tabatabai G, Wen PY, Short SC, Preusser M (2023) Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. Neuro Oncol 25(7):1200\u20131224. https:\/\/doi.org\/10.1093\/neuonc\/noad038","journal-title":"Neuro Oncol"},{"issue":"3","key":"7216_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/leu.2014.264","volume":"29","author":"I Vater","year":"2015","unstructured":"Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, Mettenmeyer N, Nazzal I, Nagel I, Gutwein J, Richter J, Buchhalter I, Russell RB, Wiestler OD, Eils R, Deckert M, Siebert R (2015) The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 29(3):677\u2013685. https:\/\/doi.org\/10.1038\/leu.2014.264","journal-title":"Leukemia"},{"issue":"1","key":"7216_CR15","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","volume":"13","author":"J Radke","year":"2022","unstructured":"Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, Hubschmann D, Toprak UH, Lopez C, Hostench XP, Borgoni S, Juraeva D, Pritsch F, Paramasivam N, Balasubramanian GP, Schlesner M, Sahay S, Weniger M, Pehl D, Radbruch H, Osterloh A, Korfel A, Misch M, Onken J, Faust K, Vajkoczy P, Moskopp D, Wang Y, Jodicke A, Trumper L, Anagnostopoulos I, Lenze D, Kuppers R, Hummel M, Schmitt CA, Wiestler OD, Wolf S, Unterberg A, Eils R, Herold-Mende C, Brors B, Consortium IM-S, Siebert R, Wiemann S, Heppner FL (2022) The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 13(1):2558. https:\/\/doi.org\/10.1038\/s41467-022-30050-y","journal-title":"Nat Commun"},{"issue":"6","key":"7216_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/neuonc\/noae032","volume":"26","author":"L Nayak","year":"2024","unstructured":"Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A, von Baumgarten L, Bromberg JEC, Ferreri AJM, Grommes C, Hoang-Xuan K, Kuhn J, Rubenstein JL, Ruda R, Weller M, Chang SM, van den Bent MJ, Wen PY, Soffietti R (2024) Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review. Neuro Oncol 26(6):993\u20131011. https:\/\/doi.org\/10.1093\/neuonc\/noae032","journal-title":"Neuro Oncol"},{"issue":"9","key":"7216_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414\u20131418. https:\/\/doi.org\/10.1038\/bjc.2011.357","journal-title":"Br J Cancer"},{"issue":"3","key":"7216_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.14073","volume":"174","author":"MS Shiels","year":"2016","unstructured":"Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G, Engels EA (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174(3):417\u2013424. https:\/\/doi.org\/10.1111\/bjh.14073","journal-title":"Br J Haematol"},{"issue":"1","key":"7216_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.23736\/S0390-5616.19.04785-4","volume":"68","author":"T Furst","year":"2024","unstructured":"Furst T, Hoffman H, Chin LS (2024) All-cause and tumor-specific mortality trends in elderly primary central nervous system lymphoma (PCNSL) patients: a surveillance, epidemiology, and end results (SEER) analysis. J Neurosurg Sci 68(1):44\u201350. https:\/\/doi.org\/10.23736\/S0390-5616.19.04785-4","journal-title":"J Neurosurg Sci"},{"issue":"7","key":"7216_CR20","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.10851","volume":"95","author":"JE Olson","year":"2002","unstructured":"Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, Kaplan RS, O\u2019Neill BP (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95(7):1504\u20131510. https:\/\/doi.org\/10.1002\/cncr.10851","journal-title":"Cancer"},{"issue":"4","key":"7216_CR21","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008\u20132012. Neuro Oncol 17(4):iv1\u2013iv62. https:\/\/doi.org\/10.1093\/neuonc\/nov189","journal-title":"Neuro Oncol"},{"issue":"9","key":"7216_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","volume":"79","author":"P Roth","year":"2012","unstructured":"Roth P, Martus P, Kiewe P, Mohle R, Klasen H, Rauch M, Roth A, Kaun S, Thiel E, Korfel A, Weller M (2012) Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 79(9):890\u2013896. https:\/\/doi.org\/10.1212\/WNL.0b013e318266fcb2","journal-title":"Neurology"},{"issue":"1","key":"7216_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2025031869","volume":"148","author":"LD Kaulen","year":"2026","unstructured":"Kaulen LD, Nayak L, Karschnia P, Kraai I, Galluzzo D, de Groot FA, Witterholt M, Donovan L, Bhella S, Kuschel LP, Fox CP, Seidel S, Paterson J, Richter B, Dixit KS, Zeyen T, Alderuccio JP, Montoto S, Kuittinen O, Traub BL, Doubrovinskaia S, Rohdjess H, Muller KJ, Enting R, de Bresser J, Kuitunen H, Iwamoto FM, Alencar A, Herrlinger U, Platten M, Cwynarski K, Mendez J, Roth P, von Baumgarten L, Prica A, Bhagat G, Lurain K, Schiff D, Vermaat JSP, Baehring JM, Nijland M, Dietrich J, Batchelor TT, Wick W (2026) Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study. Blood 148(1):58\u201370. https:\/\/doi.org\/10.1182\/blood.2025031869","journal-title":"Blood"},{"issue":"3","key":"7216_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/a:1006290032052","volume":"43","author":"M Schabet","year":"1999","unstructured":"Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neurooncol 43(3):199\u2013201. https:\/\/doi.org\/10.1023\/a:1006290032052","journal-title":"J Neurooncol"},{"issue":"6","key":"7216_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CCO.0b013e32834b6adc","volume":"23","author":"A Gonzalez-Aguilar","year":"2011","unstructured":"Gonzalez-Aguilar A, Soto-Hernandez JL (2011) The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol 23(6):648\u2013653. https:\/\/doi.org\/10.1097\/CCO.0b013e32834b6adc","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"7216_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10428190400015733","volume":"46","author":"T Wolf","year":"2005","unstructured":"Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU (2005) Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin\u2019s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 46(2):207\u2013215. https:\/\/doi.org\/10.1080\/10428190400015733","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7216_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/nop\/npw033","volume":"4","author":"A Korfel","year":"2017","unstructured":"Korfel A, Schlegel U, Johnson DR, Kaufmann TJ, Giannini C, Hirose T (2017) Case-based review: primary central nervous system lymphoma. Neurooncol Pract 4(1):46\u201359. https:\/\/doi.org\/10.1093\/nop\/npw033","journal-title":"Neurooncol Pract"},{"issue":"2","key":"7216_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/OP.23.00294","volume":"20","author":"CR D'Angelo","year":"2024","unstructured":"D\u2019Angelo CR (2024) Diagnostic, pathologic, and therapeutic considerations for primary CNS lymphoma. JCO Oncol Pract 20(2):195\u2013202. https:\/\/doi.org\/10.1200\/OP.23.00294","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"7216_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11912-015-0457-x","volume":"17","author":"C Sarkozy","year":"2015","unstructured":"Sarkozy C, Salles G, Falandry C (2015) The biology of aging and lymphoma: a complex interplay. Curr Oncol Rep 17(7):32. https:\/\/doi.org\/10.1007\/s11912-015-0457-x","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"7216_CR30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d\u2019Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229\u20131253. https:\/\/doi.org\/10.1182\/blood.2022015851","journal-title":"Blood"},{"issue":"2","key":"7216_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/sj.leu.2405019","volume":"22","author":"M Montesinos-Rongen","year":"2008","unstructured":"Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, Schaller C, Reifenberger G, Rubenstein J, Wiestler OD, Spang R, Dalla-Favera R, Siebert R, Deckert M (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22(2):400\u2013405. https:\/\/doi.org\/10.1038\/sj.leu.2405019","journal-title":"Leukemia"},{"issue":"2","key":"7216_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","volume":"34","author":"I Hernandez-Verdin","year":"2023","unstructured":"Hernandez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-Sanchez F, Ibanez-Julia MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reynies A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A (2023) Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol 34(2):186\u2013199. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.002","journal-title":"Ann Oncol"},{"issue":"17","key":"7216_CR33","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","volume":"21","author":"E Braggio","year":"2015","unstructured":"Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O\u2019Neill BP (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21(17):3986\u20133994. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2116","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7216_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/CCO.0000000000000978","volume":"35","author":"L Lebrun","year":"2023","unstructured":"Lebrun L, Allard-Demoustiez S, Salmon I (2023) Pathology and new insights in central nervous system lymphomas. Curr Opin Oncol 35(5):347\u2013356. https:\/\/doi.org\/10.1097\/CCO.0000000000000978","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"7216_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Broet","year":"2006","unstructured":"Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107(1):190\u2013196. https:\/\/doi.org\/10.1182\/blood-2005-03-1024","journal-title":"Blood"},{"issue":"5","key":"7216_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"issue":"7","key":"7216_CR37","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127(7):869\u2013881. https:\/\/doi.org\/10.1182\/blood-2015-10-673236","journal-title":"Blood"},{"issue":"7332","key":"7216_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115\u2013119. https:\/\/doi.org\/10.1038\/nature09671","journal-title":"Nature"},{"issue":"6","key":"7216_CR39","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/bjh.18758","volume":"201","author":"C Bravetti","year":"2023","unstructured":"Bravetti C, Degaud M, Armand M, Sourdeau E, Mokhtari K, Maloum K, Osman J, Verrier P, Houillier C, Roos-Weil D, Soussain C, Choquet S, Hoang-Xuan K, Le Garff-Tavernier M, Denis JA, Davi F (2023) Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma. Br J Haematol 201(6):1088\u20131096. https:\/\/doi.org\/10.1111\/bjh.18758","journal-title":"Br J Haematol"},{"issue":"7277","key":"7216_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392. https:\/\/doi.org\/10.1038\/nature08638","journal-title":"Nature"},{"issue":"9","key":"7216_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7(9):1018\u20131029. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0613","journal-title":"Cancer Discov"},{"issue":"10","key":"7216_CR42","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/hem3.70024","volume":"8","author":"A Rivas-Delgado","year":"2024","unstructured":"Rivas-Delgado A, Lopez C, Clot G, Nadeu F, Grau M, Frigola G, Bosch-Schips J, Radke J, Ishaque N, Alcoceba M, Tapia G, Luizaga L, Barcena C, Kelleher N, Villamor N, Baumann T, Muntanola A, Sancho-Cia JM, Garcia-Sancho AM, Gonzalez-Barca E, Matutes E, Brito JA, Karube K, Salaverria I, Enjuanes A, Wiemann S, Heppner FL, Siebert R, Climent F, Campo E, Gine E, Lopez-Guillermo A, Bea S (2024) Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL. Hemasphere 8(10):e70024. https:\/\/doi.org\/10.1002\/hem3.70024","journal-title":"Hemasphere"},{"issue":"3","key":"7216_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11060-018-2990-6","volume":"140","author":"S Zorofchian","year":"2018","unstructured":"Zorofchian S, El-Achi H, Yan Y, Esquenazi Y, Ballester LY (2018) Characterization of genomic alterations in primary central nervous system lymphomas. J Neurooncol 140(3):509\u2013517. https:\/\/doi.org\/10.1007\/s11060-018-2990-6","journal-title":"J Neurooncol"},{"issue":"4","key":"7216_CR44","doi-asserted-by":"publisher","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","volume":"6","author":"M Nijland","year":"2017","unstructured":"Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A (2017) HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? Oncoimmunology 6(4):e1295202. https:\/\/doi.org\/10.1080\/2162402X.2017.1295202","journal-title":"Oncoimmunology"},{"issue":"13","key":"7216_CR45","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1182\/blood.2021011366","volume":"138","author":"M Minderman","year":"2021","unstructured":"Minderman M, Amir A, Kraan W, Schilder-Tol EJM, Oud M, Scheepstra CG, Noorduyn AL, Kluin PM, Kersten MJ, Spaargaren M, Pals ST (2021) Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1\/PD-L1\/PD-L2 alterations. Blood 138(13):1194\u20131197. https:\/\/doi.org\/10.1182\/blood.2021011366","journal-title":"Blood"},{"issue":"6","key":"7216_CR46","doi-asserted-by":"publisher","first-page":"e3313","DOI":"10.1002\/hon.3313","volume":"42","author":"B Primeaux","year":"2024","unstructured":"Primeaux B, Luo C, Yeung EK, Linger C, Chen S, Do B (2024) Characterizing second line and beyond therapies for primary central nervous system lymphomas. Hematol Oncol 42(6):e3313. https:\/\/doi.org\/10.1002\/hon.3313","journal-title":"Hematol Oncol"},{"issue":"4","key":"7216_CR47","doi-asserted-by":"publisher","first-page":"e0319714","DOI":"10.1371\/journal.pone.0319714","volume":"20","author":"E Uawithya","year":"2025","unstructured":"Uawithya E, Kulchutisin K, Jitprapaikulsan J, Leelakanok N, Owattanapanich W (2025) Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: a systematic review and meta-analysis. PLoS ONE 20(4):e0319714. https:\/\/doi.org\/10.1371\/journal.pone.0319714","journal-title":"PLoS ONE"},{"issue":"6","key":"7216_CR48","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2352-3026(26)00098-0","volume":"13","author":"JLM van Rooij","year":"2026","unstructured":"van Rooij JLM, Wessels PH, Niers JM, Bromberg JEC, Gijtenbeek JMM, van Haastert R, Ruven HJT, Meek B, Verbeek MM, Solleveld-Westerink N, de Leng WWJ, Muhlebner A, Langerak AW, Berendsen S, Knol EF, van Alkemade H, Seute T, Minnema MC, Nierkens S, Snijders TJ (2026) Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study. Lancet Haematol 13(6):e376\u2013e385. https:\/\/doi.org\/10.1016\/S2352-3026(26)00098-0","journal-title":"Lancet Haematol"},{"issue":"23","key":"7216_CR49","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121(23):4740\u20134748. https:\/\/doi.org\/10.1182\/blood-2013-01-476333","journal-title":"Blood"},{"issue":"4","key":"7216_CR50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/neuonc\/noae251","volume":"27","author":"L Hai","year":"2025","unstructured":"Hai L, Friedel D, Hinz F, Hoffmann DC, Doubrovinskaia S, Rohdjess H, Weidenauer K, Denisova E, Scheffler GT, Kessler T, Kourtesakis A, Herold-Mende C, Henegariu O, Baehring JM, Dietrich J, Brors B, Wick W, Sahm F, Kaulen LD (2025) Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. Neuro Oncol 27(4):979\u2013992. https:\/\/doi.org\/10.1093\/neuonc\/noae251","journal-title":"Neuro Oncol"},{"issue":"3","key":"7216_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00401-023-02613-w","volume":"146","author":"LD Kaulen","year":"2023","unstructured":"Kaulen LD, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann DC, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring JM, Brors B, Sahm F, Wick W (2023) Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. Acta Neuropathol 146(3):499\u2013514. https:\/\/doi.org\/10.1007\/s00401-023-02613-w","journal-title":"Acta Neuropathol"},{"issue":"8","key":"7216_CR52","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1080\/09273948.2023.2287061","volume":"32","author":"DA Balikov","year":"2024","unstructured":"Balikov DA, Conway K, Brown NA, Camelo-Piragua S, Rao RC (2024) Molecular analysis of liquid vitreous biopsy reveals occult lymphoma following cytology-negative biopsies of the brain and vitreous. Ocul Immunol Inflamm 32(8):1689\u20131697. https:\/\/doi.org\/10.1080\/09273948.2023.2287061","journal-title":"Ocul Immunol Inflamm"},{"issue":"17","key":"7216_CR53","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood.2020008235","volume":"138","author":"C Soussain","year":"2021","unstructured":"Soussain C, Malaise D, Cassoux N (2021) Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood 138(17):1519\u20131534. https:\/\/doi.org\/10.1182\/blood.2020008235","journal-title":"Blood"},{"issue":"3","key":"7216_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4065\/70.3.256","volume":"70","author":"SE Schild","year":"1995","unstructured":"Schild SE, Wharen RE Jr., Menke DM, Folger WN, Colon-Otero G (1995) Primary lymphoma of the spinal cord. Mayo Clin Proc 70(3):256\u2013260. https:\/\/doi.org\/10.4065\/70.3.256","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"7216_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/j.sult.2023.02.003","volume":"44","author":"R Capasso","year":"2023","unstructured":"Capasso R, Negro A, Russo C, Zeccolini F, Muto G, Caranci FP, Pinto A (2023) Conventional and advanced MRI techniques in the evaluation of primary CNS lymphoma. Semin Ultrasound CT MR 44(3):126\u2013135. https:\/\/doi.org\/10.1053\/j.sult.2023.02.003","journal-title":"Semin Ultrasound CT MR"},{"key":"7216_CR56","doi-asserted-by":"publisher","first-page":"882334","DOI":"10.3389\/fneur.2022.882334","volume":"13","author":"X Du","year":"2022","unstructured":"Du X, He Y, Lin W (2022) Diagnostic accuracy of the diffusion-weighted imaging method used in association with the apparent diffusion coefficient for differentiating between primary central nervous system lymphoma and high-grade glioma: systematic review and meta-analysis. Front Neurol 13:882334. https:\/\/doi.org\/10.3389\/fneur.2022.882334","journal-title":"Front Neurol"},{"issue":"7","key":"7216_CR57","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.31557\/APJCP.2022.23.7.2449","volume":"23","author":"R Mulyadi","year":"2022","unstructured":"Mulyadi R, Handoko H, Zairinal RA, Prihartono J (2022) The role of pretherapeutic diffusion-weighted MR imaging derived apparent diffusion coefficient in predicting clinical outcomes in immunocompetent patients with primary CNS lymphoma: a systematic review and meta-analysis. Asian Pac J Cancer Prev 23(7):2449\u20132457. https:\/\/doi.org\/10.31557\/APJCP.2022.23.7.2449","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"7216_CR58","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","volume":"23","author":"RF Barajas","year":"2021","unstructured":"Barajas RF, Politi LS, Anzalone N, Schoder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23(7):1056\u20131071. https:\/\/doi.org\/10.1093\/neuonc\/noab020","journal-title":"Neuro Oncol"},{"issue":"2","key":"7216_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/19714009251354883","volume":"39","author":"N Jittapiromsak","year":"2026","unstructured":"Jittapiromsak N, Sriinkua P, Nimitpornsuko P, Jittapiromsak P (2026) Diffusion-weighted imaging and susceptibility-weighted imaging in differentiating ring-enhancing primary central nervous system lymphoma from infections. Neuroradiol J 39(2):204\u2013215. https:\/\/doi.org\/10.1177\/19714009251354883","journal-title":"Neuroradiol J"},{"issue":"5","key":"7216_CR60","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3171\/foc.2006.21.5.16","volume":"21","author":"AF Eichler","year":"2006","unstructured":"Eichler AF, Batchelor TT (2006) Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 21(5):E15. https:\/\/doi.org\/10.3171\/foc.2006.21.5.16","journal-title":"Neurosurg Focus"},{"issue":"1","key":"7216_CR61","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","volume":"15","author":"T Chen","year":"2022","unstructured":"Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, Geng D, Yu JT, Li Y, Li XQ, Chen H, Zhuang D, Li J, Wang B, Jiang T, Lyu L, Song Y, Qiu X, Li W, Lin S, Zhang X, Lu D, Lei J, Chen Y, Mao Y (2022) Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. J Hematol Oncol 15(1):136. https:\/\/doi.org\/10.1186\/s13045-022-01356-7","journal-title":"J Hematol Oncol"},{"issue":"4","key":"7216_CR62","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10143-018-0946-0","volume":"41","author":"G Jahr","year":"2018","unstructured":"Jahr G, Da Broi M, Holte H Jr., Beiske K, Meling TR (2018) The role of surgery in intracranial PCNSL. Neurosurg Rev 41(4):1037\u20131044. https:\/\/doi.org\/10.1007\/s10143-018-0946-0","journal-title":"Neurosurg Rev"},{"issue":"5","key":"7216_CR63","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1017\/cjn.2016.255","volume":"43","author":"M Binnahil","year":"2016","unstructured":"Binnahil M, Au K, Lu JQ, Wheatley BM, Sankar T (2016) The influence of corticosteroids on diagnostic accuracy of biopsy for primary Central Nervous System lymphoma. Can J Neurol Sci 43(5):721\u2013725. https:\/\/doi.org\/10.1017\/cjn.2016.255","journal-title":"Can J Neurol Sci"},{"issue":"12","key":"7216_CR64","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/neuonc\/noab109","volume":"23","author":"M Margold","year":"2021","unstructured":"Margold M, Seidel S, Kowalski T, Ladigan-Badura S, Baraniskin A, Schroers R, Frey AV, Schmidt-Wolf IGH, Herrlinger U, Korfel A, Schlegel U (2021) The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol 23(12):2076\u20132084. https:\/\/doi.org\/10.1093\/neuonc\/noab109","journal-title":"Neuro Oncol"},{"issue":"10","key":"7216_CR65","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1182\/blood.2024023832","volume":"144","author":"M Gupta","year":"2024","unstructured":"Gupta M, Bradley JD, Massaad E, Burns EJ, Georgantas NZ, Maron GE, Batten JM, Gallagher A, Thierauf J, Nayyar N, Gordon A, Jones SS, Pisapia M, Sun Y, Jones PS, Barker FG 2nd, Curry WT, Gupta R, Romero JM, Wang N, Brastianos PK, Martinez-Lage M, Tateishi K, Forst DA, Nahed BV, Batchelor TT, Ritterhouse LL, Iser F, Kessler T, Jordan JT, Dietrich J, Meyerson M, Cahill DP, Lennerz JK, Carter BS, Shankar GM (2024) Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma. Blood 144(10):1093\u20131100. https:\/\/doi.org\/10.1182\/blood.2024023832","journal-title":"Blood"},{"issue":"9","key":"7216_CR66","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.22.00826","volume":"41","author":"JA Mutter","year":"2023","unstructured":"Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kuhn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F (2023) Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J Clin Oncol 41(9):1684\u20131694. https:\/\/doi.org\/10.1200\/JCO.22.00826","journal-title":"J Clin Oncol"},{"issue":"6","key":"7216_CR67","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood.2023022020","volume":"143","author":"JM Heger","year":"2024","unstructured":"Heger JM, Mattlener J, Schneider J, Godel P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Ruess D, Ruge MI, Montesinos-Rongen M, Deckert M, Blau T, Kutsch N, Balke-Want H, Weiss J, Becker K, Reinhardt HC, Hallek M, Borchmann P, von Tresckow B, Borchmann S (2024) Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood 143(6):522\u2013534. https:\/\/doi.org\/10.1182\/blood.2023022020","journal-title":"Blood"},{"issue":"1","key":"7216_CR68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13148-021-01091-9","volume":"13","author":"BM Downs","year":"2021","unstructured":"Downs BM, Ding W, Cope LM, Umbricht CB, Li W, He H, Ke X, Holdhoff M, Bettegowda C, Tao W, Sukumar S (2021) Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. Clin Epigenetics 13(1):104. https:\/\/doi.org\/10.1186\/s13148-021-01091-9","journal-title":"Clin Epigenetics"},{"issue":"7","key":"7216_CR69","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/S2352-3026(24)00104-2","volume":"11","author":"T Calimeri","year":"2024","unstructured":"Calimeri T, Anzalone N, Cangi MG, Fiore P, Gagliardi F, Miserocchi E, Ponzoni M, Ferreri AJM (2024) Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88(Leu265Pro) and IL-10. Lancet Haematol 11(7):e540\u2013e549. https:\/\/doi.org\/10.1016\/S2352-3026(24)00104-2","journal-title":"Lancet Haematol"},{"issue":"9","key":"7216_CR70","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Grommes C (2022) Primary central nervous system lymphoma. Blood 140(9):971\u2013979. https:\/\/doi.org\/10.1182\/blood.2020008377","journal-title":"Blood"},{"issue":"11","key":"7216_CR71","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Roth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithauser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nagele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036\u20131047. https:\/\/doi.org\/10.1016\/S1470-2045(10)70229-1","journal-title":"Lancet Oncol"},{"issue":"9","key":"7216_CR72","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9):1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"issue":"5","key":"7216_CR73","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosee PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Ruda R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gorlov JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217-227. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"issue":"12","key":"7216_CR74","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","volume":"8","author":"TT Batchelor","year":"2024","unstructured":"Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL (2024) Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv 8(12):3189\u20133199. https:\/\/doi.org\/10.1182\/bloodadvances.2023011657","journal-title":"Blood Adv"},{"issue":"16","key":"7216_CR75","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/bloodadvances.2022007011","volume":"6","author":"P Lesueur","year":"2022","unstructured":"Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, Fabbro M, Agape P, Molucon-Chabrot C, Chebrek S, Alentorn A, Feuvret L, Delgadillo D, Stefan D, Choquet S, Nichelli L, Mokhtari K, Mathon B, Dureau S, Soussain C, Houillier C (2022) Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv 6(16):4807\u20134815. https:\/\/doi.org\/10.1182\/bloodadvances.2022007011","journal-title":"Blood Adv"},{"issue":"7","key":"7216_CR76","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fossa A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O\u2019Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 26(7):1305\u20131313. https:\/\/doi.org\/10.1093\/annonc\/mdv076","journal-title":"Ann Oncol"},{"issue":"5","key":"7216_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/CCO.0000000000000981","volume":"35","author":"A Bertucci","year":"2023","unstructured":"Bertucci A, Harlay V, Chinot O, Tabouret E (2023) Primary central nervous system lymphoma (PCNSL) in older patients. Curr Opin Oncol 35(5):373\u2013381. https:\/\/doi.org\/10.1097\/CCO.0000000000000981","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"7216_CR78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2019.05.012","volume":"19","author":"G Faivre","year":"2019","unstructured":"Faivre G, Butler MJ, Le I, Brenner A (2019) Temozolomide as a single agent maintenance therapy in elderly patients with primary CNS lymphoma. Clin Lymphoma Myeloma Leuk 19(10):665\u2013669. https:\/\/doi.org\/10.1016\/j.clml.2019.05.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7216_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-026-05492-9","author":"X Chang","year":"2026","unstructured":"Chang X, He Z, Wang H, Zhu H, Guo Y, Zou D, Zhao Z, Song T, Hu R, Ni J, Zhao H, Hui W, Liu Z, Li Z, Zhang W, Zhou D, Zhang Y, Sun W (2026) Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-026-05492-9","journal-title":"J Neurooncol"},{"issue":"8","key":"7216_CR80","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/annonc\/mdz142","volume":"30","author":"JL Rubenstein","year":"2019","unstructured":"Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B (2019) Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol 30(8):1397\u20131398. https:\/\/doi.org\/10.1093\/annonc\/mdz142","journal-title":"Ann Oncol"},{"issue":"4","key":"7216_CR81","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/neuonc\/noad015","volume":"25","author":"JEC Bromberg","year":"2023","unstructured":"Bromberg JEC, Doorduijn JK (2023) Is there a future for maintenance temozolomide chemotherapy in PCNSL? Neuro Oncol 25(4):699\u2013700. https:\/\/doi.org\/10.1093\/neuonc\/noad015","journal-title":"Neuro Oncol"},{"issue":"13","key":"7216_CR82","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B (2018) Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2(13):1595\u20131607. https:\/\/doi.org\/10.1182\/bloodadvances.2017014845","journal-title":"Blood Adv"},{"issue":"4","key":"7216_CR83","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.esmoop.2021.100213","volume":"6","author":"T Calimeri","year":"2021","unstructured":"Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM (2021) How we treat primary central nervous system lymphoma. ESMO Open 6(4):100213. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213","journal-title":"ESMO Open"},{"issue":"6","key":"7216_CR84","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31(6):833-843 e835. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.012","journal-title":"Cancer Cell"},{"issue":"1","key":"7216_CR85","doi-asserted-by":"publisher","first-page":"vdae037","DOI":"10.1093\/noajnl\/vdae037","volume":"6","author":"H Yonezawa","year":"2024","unstructured":"Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R (2024) Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neurooncol Adv 6(1):vdae037. https:\/\/doi.org\/10.1093\/noajnl\/vdae037","journal-title":"Neurooncol Adv"},{"issue":"1","key":"7216_CR86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R (2021) Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol 23(1):122\u2013133. https:\/\/doi.org\/10.1093\/neuonc\/noaa145","journal-title":"Neuro Oncol"},{"issue":"1","key":"7216_CR87","doi-asserted-by":"publisher","first-page":"vdad109","DOI":"10.1093\/noajnl\/vdad109","volume":"5","author":"Y Arakawa","year":"2023","unstructured":"Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R (2023) Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I\/II study of tirabrutinib. Neurooncol Adv 5(1):vdad109. https:\/\/doi.org\/10.1093\/noajnl\/vdad109","journal-title":"Neurooncol Adv"},{"issue":"5","key":"7216_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000537995","volume":"147","author":"Z Lin","year":"2024","unstructured":"Lin Z, Ma J, Ma Y, Li Q, Kang H, Zhang M, Chen B (2024) Zanubrutinib plus cytarabine in patients with refractory\/relapsed primary central nervous system lymphoma. Acta Haematol 147(5):555\u2013563. https:\/\/doi.org\/10.1159\/000537995","journal-title":"Acta Haematol"},{"issue":"9","key":"7216_CR89","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-22-1682","volume":"29","author":"CA Von Roemeling","year":"2023","unstructured":"Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, Li C, Russell RA, Kanumuri RS, Sharma A, Tun HW, Mitchell DA (2023) Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases. Clin Cancer Res 29(9):1751\u20131762. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1682","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7216_CR90","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molucon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C (2019) Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger. Ann Oncol 30(4):621\u2013628. https:\/\/doi.org\/10.1093\/annonc\/mdz032","journal-title":"Ann Oncol"},{"issue":"21","key":"7216_CR91","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","volume":"132","author":"HW Tun","year":"2018","unstructured":"Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O\u2019Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE (2018) Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma. Blood 132(21):2240\u20132248. https:\/\/doi.org\/10.1182\/blood-2018-02-835496","journal-title":"Blood"},{"issue":"2","key":"7216_CR92","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4143\/crt.2024.531","volume":"57","author":"JH Yi","year":"2025","unstructured":"Yi JH, Kim SJ, Kim SA, Jung J, Yoon DH (2025) Nivolumab in relapsed or refractory primary central nervous system lymphoma: multicenter, retrospective study. Cancer Res Treat 57(2):590\u2013596. https:\/\/doi.org\/10.4143\/crt.2024.531","journal-title":"Cancer Res Treat"},{"key":"7216_CR93","unstructured":"ClinicalTrials.gov (2016) A phase 2, open-label, single-arm, two-cohort study of Nivolumab in Relapsed\/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed\/Refractory Primary Testicular Lymphoma (PTL). ClinicalTrials.gov identifier NCT02857426. (2016) https:\/\/clinicaltrials.gov\/study\/NCT02857426. Accessed 20 July 2026"},{"key":"7216_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-141773","volume":"136","author":"K Hoang-Xuan","year":"2020","unstructured":"Hoang-Xuan K, Houot R, Soussain C, Blonski M, Schmitt A, Delwail V, Damaj G, Ghesquieres H, Peyrade F, Tempescul A, Abraham J, Agape P, Ahle G, Baize N, Bories P, Campello C, Gyan E, Jardin F, Rey P, Massard C (2020) First results of the Acs\u00e9 pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort. Blood 136:15\u201316. https:\/\/doi.org\/10.1182\/blood-2020-141773","journal-title":"Blood"},{"issue":"15","key":"7216_CR95","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","volume":"34","author":"A Korfel","year":"2016","unstructured":"Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P (2016) Phase II Trial of Temsirolimus for Relapsed\/Refractory Primary CNS Lymphoma. J Clin Oncol 34(15):1757\u20131763. https:\/\/doi.org\/10.1200\/JCO.2015.64.9897","journal-title":"J Clin Oncol"},{"issue":"15","key":"7216_CR96","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O\u2019Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB (2022) Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood 139(15):2306\u20132315. https:\/\/doi.org\/10.1182\/blood.2021014738","journal-title":"Blood"},{"issue":"16_suppl","key":"7216_CR97","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","volume":"42","author":"L Nayak","year":"2024","unstructured":"Nayak L, Chukwueke UN, Meehan C, Redd R, Hogan S, Lee EQ, Kim AI, Arrillaga-Romany I, Figueroa JRRM, Castro LNG, Murakami MA, Huang RY-k, Gerdemann U, Kaminski J, Filosto S, Poddar S, Mattie M, Armand P, Kean L, Jacobson CA (2024) A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). J Clin Oncol 42(16_suppl):2006\u20132006. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2006","journal-title":"J Clin Oncol"},{"key":"7216_CR98","unstructured":"U.S. Food and Drug Administration (2026) 2026 Biological license application supplement noteworthy approvals. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/2026-biological-license-application-supplement-noteworthy-approvals. Accessed 19 July 2026"},{"key":"7216_CR99","unstructured":"U.S. Food and Drug Administration (2026) YESCARTA (axicabtagene ciloleucel). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta. Accessed 24 July 2026"},{"issue":"16","key":"7216_CR100","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1182\/blood.2025028964","volume":"146","author":"LD Kaulen","year":"2025","unstructured":"Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J (2025) Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood 146(16):1902\u20131913. https:\/\/doi.org\/10.1182\/blood.2025028964","journal-title":"Blood"},{"issue":"12","key":"7216_CR101","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J (2023) Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol 25(12):2239\u20132249. https:\/\/doi.org\/10.1093\/neuonc\/noad118","journal-title":"Neuro Oncol"},{"issue":"1","key":"7216_CR102","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-025-01761-8","volume":"19","author":"LD Kaulen","year":"2026","unstructured":"Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Soumerai JD, Martinez-Lage M, Haydu JE, Shankar GM, Patel C, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J (2026) Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma. J Hematol Oncol 19(1):2. https:\/\/doi.org\/10.1186\/s13045-025-01761-8","journal-title":"J Hematol Oncol"},{"issue":"9","key":"7216_CR103","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.3390\/curroncol29090522","volume":"29","author":"P Du","year":"2022","unstructured":"Du P, Chen H, Shen L, Liu X, Wu X, Chen L, Cao A, Geng D (2022) Analysis of key factors associated with response to salvage high-dose methotrexate rechallenge in primary central nervous system lymphoma with first relapse. Curr Oncol 29(9):6642\u20136656. https:\/\/doi.org\/10.3390\/curroncol29090522","journal-title":"Curr Oncol"},{"issue":"20","key":"7216_CR104","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1182\/bloodadvances.2021004779","volume":"5","author":"CP Fox","year":"2021","unstructured":"Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K (2021) A phase 1\/2 study of thiotepa-based immunochemotherapy in relapsed\/refractory primary CNS lymphoma: the TIER trial. Blood Adv 5(20):4073\u20134082. https:\/\/doi.org\/10.1182\/bloodadvances.2021004779","journal-title":"Blood Adv"},{"key":"7216_CR105","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.977","author":"DH Kim","year":"2025","unstructured":"Kim DH, An S, Ahn H, Song H, Kang KW, Yoon SE, Kim SJ, Kim HJ, Koh Y, Yang DH, Consortium for Improving Survival of Lymphoma (2025) Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib in relapsed or refractory primary central nervous system lymphoma: a multi-center, phase II study. Cancer Res Treat. https:\/\/doi.org\/10.4143\/crt.2025.977","journal-title":"Cancer Res Treat"},{"issue":"1","key":"7216_CR106","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/16078454.2021.2019363","volume":"27","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xu X (2022) Application of new targeted drugs in relapsed\/refractory primary central nervous system lymphoma. Hematology (United States) 27(1):105\u2013112. https:\/\/doi.org\/10.1080\/16078454.2021.2019363","journal-title":"Hematology (United States)"},{"issue":"12","key":"7216_CR107","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11910-024-01376-5","volume":"24","author":"E Aquilanti","year":"2024","unstructured":"Aquilanti E, Herrity E, Nayak L (2024) Novel therapies for primary central nervous system lymphomas. Curr Neurol Neurosci Rep 24(12):621\u2013629. https:\/\/doi.org\/10.1007\/s11910-024-01376-5","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"7216_CR108","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/bmt.2017.23","volume":"52","author":"E Schorb","year":"2017","unstructured":"Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B (2017) High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant 52(8):1113\u20131119. https:\/\/doi.org\/10.1038\/bmt.2017.23","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"7216_CR109","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.clml.2024.11.008","volume":"25","author":"R Puckrin","year":"2025","unstructured":"Puckrin R, Stewart C, Owen C, Street LE, Perry S, Duggan P, Shafey M, Chua N, Stewart DA (2025) De-escalated induction therapy and thiotepa\/busulfan-based autologous stem cell transplantation for primary central nervous system lymphoma. Clin Lymphoma Myeloma Leuk 25(4):265\u2013270. https:\/\/doi.org\/10.1016\/j.clml.2024.11.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"7216_CR110","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-023-04504-2","volume":"165","author":"MK Ko","year":"2023","unstructured":"Ko MK, Kwak YK, Choi BO, Jeun SS, Park JS, Ahn S, Song JH (2023) Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose? J Neurooncol 165(2):321\u2013328. https:\/\/doi.org\/10.1007\/s11060-023-04504-2","journal-title":"J Neurooncol"},{"issue":"7","key":"7216_CR111","doi-asserted-by":"publisher","first-page":"622","DOI":"10.11406\/rinketsu.65.622","volume":"65","author":"F Fujii","year":"2024","unstructured":"Fujii F, Terao T, Nishimori H, Fujii K, Matsuo T, Yoshino T, Ueda H, Oyama T, Matsumura A, Kondo K, Matsubara C, Fujiwara K, Seike K, Fujiwara H, Asada N, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Maeda Y (2024) Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation. Rinsho Ketsueki 65(7):622\u2013627. https:\/\/doi.org\/10.11406\/rinketsu.65.622","journal-title":"Rinsho Ketsueki"},{"issue":"4","key":"7216_CR112","doi-asserted-by":"publisher","first-page":"e071350","DOI":"10.1136\/bmjopen-2022-071350","volume":"13","author":"F Yamasaki","year":"2023","unstructured":"Yamasaki F, Fudaba H, Asano K, Sasayama T, Natsumeda M, Shimabukuro T, Taguchi K, Koizumi S, Nakayama N, Fujii K, Nishibuchi I, Sugiyama K, Yoshida K, Yonezawa U, Yasutomo M, Kawasaki Y, Kakuta K, Katayama K, Tanaka K, Nagashima H, Tsukamoto Y, Ideguchi M, Nishizaki T, Kurozumi K, Hosoya T, Akita T, Kambe A (2023) Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study. BMJ Open 13(4):e071350. https:\/\/doi.org\/10.1136\/bmjopen-2022-071350","journal-title":"BMJ Open"},{"issue":"12","key":"7216_CR113","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.1002\/jcp.29790","volume":"235","author":"H Yang","year":"2020","unstructured":"Yang H, Xun Y, Yang A, Liu F, You H (2020) Advances and challenges in the treatment of primary central nervous system lymphoma. J Cell Physiol 235(12):9143\u20139165. https:\/\/doi.org\/10.1002\/jcp.29790","journal-title":"J Cell Physiol"},{"issue":"11","key":"7216_CR114","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1212\/WNL.0000000000003097","volume":"87","author":"DM Gazzola","year":"2016","unstructured":"Gazzola DM, Arbini AA, Haglof K, Pacia SV (2016) Primary marginal zone lymphoma of the CNS presenting as a diffuse leptomeningeal process. Neurology 87(11):1180\u20131182. https:\/\/doi.org\/10.1212\/WNL.0000000000003097","journal-title":"Neurology"},{"issue":"12","key":"7216_CR115","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00277-011-1225-0","volume":"90","author":"T Lim","year":"2011","unstructured":"Lim T, Kim SJ, Kim K, Lee JI, Lim DH, Lee DJ, Baek KK, Lee HY, Han B, Uhm JE, Ko YH, Kim WS (2011) Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol 90(12):1391\u20131398. https:\/\/doi.org\/10.1007\/s00277-011-1225-0","journal-title":"Ann Hematol"},{"issue":"1","key":"7216_CR116","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.19238","volume":"204","author":"E Flospergher","year":"2024","unstructured":"Flospergher E, Marino F, Calimeri T, Cangi MG, Ferreri AJM, Ponzoni M, Bongiovanni L (2024) Primary central nervous system marginal zone lymphoma. Br J Haematol 204(1):31\u201344. https:\/\/doi.org\/10.1111\/bjh.19238","journal-title":"Br J Haematol"},{"issue":"2","key":"7216_CR117","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1309\/LM85GPXDT8NJSDAB","volume":"46","author":"M Guzzetta","year":"2015","unstructured":"Guzzetta M, Drexler S, Buonocore B, Donovan V (2015) Primary CNS T-cell lymphoma of the spinal cord: case report and literature review. Lab Med 46(2):159\u2013163. https:\/\/doi.org\/10.1309\/LM85GPXDT8NJSDAB","journal-title":"Lab Med"},{"issue":"7","key":"7216_CR118","doi-asserted-by":"publisher","first-page":"e214744","DOI":"10.1212\/WNL.0000000000214744","volume":"106","author":"KJ Muller","year":"2026","unstructured":"Muller KJ, Karschnia P, Kaulen LD, Reis J, Gakis G, Englert B, Hinz F, Traub BL, Ehret F, Conner EC, Martinez-Lage M, Stoecklein VM, Dreyling M, Weigert O, Subklewe M, Rudelius M, Albert NL, Straube A, Forbrig R, Schoeberl F, Ringel F, Harter PN, Dietrich J, Von Baumgarten LD (2026) Clinical manifestations of primary CNS T-cell lymphoma: a retrospective study of histopathologic, molecular, and neuroimaging features. Neurology 106(7):e214744. https:\/\/doi.org\/10.1212\/WNL.0000000000214744","journal-title":"Neurology"},{"key":"7216_CR119","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.critrevonc.2021.103341","volume":"161","author":"J Jelicic","year":"2021","unstructured":"Jelicic J, Stauffer Larsen T, Bukumiric Z, Juul-Jensen K, Andjelic B (2021) Prognostic models in primary central nervous system lymphoma patients: A systematic review. Crit Rev Oncol Hematol 161:103341. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103341","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"7216_CR120","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/hon.2021","volume":"31","author":"H Ghesquieres","year":"2013","unstructured":"Ghesquieres H, Drouet Y, Sunyach MP, Sebban C, Chassagne-Clement C, Jouanneau E, Honnorat J, Biron P, Blay JY (2013) Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. Hematol Oncol 31(2):57\u201364. https:\/\/doi.org\/10.1002\/hon.2021","journal-title":"Hematol Oncol"},{"issue":"2","key":"7216_CR121","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell\u2019Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266\u2013272. https:\/\/doi.org\/10.1200\/JCO.2003.09.139","journal-title":"J Clin Oncol"},{"issue":"36","key":"7216_CR122","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/jco.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711\u20135715. https:\/\/doi.org\/10.1200\/jco.2006.08.2941","journal-title":"J Clin Oncol"},{"issue":"1","key":"7216_CR123","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1038\/s41598-020-65463-6","volume":"10","author":"Y Takashima","year":"2020","unstructured":"Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R (2020) GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Sci Rep 10(1):8435. https:\/\/doi.org\/10.1038\/s41598-020-65463-6","journal-title":"Sci Rep"},{"issue":"22","key":"7216_CR124","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O\u2019Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNSLCG (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034\u20135043. https:\/\/doi.org\/10.1200\/JCO.2005.13.524","journal-title":"J Clin Oncol"},{"issue":"4","key":"7216_CR125","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1212\/wnl.62.4.532","volume":"62","author":"BP O'Neill","year":"2004","unstructured":"O\u2019Neill BP (2004) Neurocognitive outcomes in primary CNS lymphoma (PCNSL). Neurology 62(4):532\u2013533. https:\/\/doi.org\/10.1212\/wnl.62.4.532","journal-title":"Neurology"},{"issue":"4","key":"7216_CR126","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/neuonc\/noad224","volume":"26","author":"JEC Bromberg","year":"2024","unstructured":"Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK (2024) Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: final results of the HOVON 105\/ALLG NHL 24 study. Neuro Oncol 26(4):724\u2013734. https:\/\/doi.org\/10.1093\/neuonc\/noad224","journal-title":"Neuro Oncol"},{"issue":"8","key":"7216_CR127","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(18)30356-5","volume":"19","author":"M van der Meulen","year":"2018","unstructured":"van der Meulen M, Dirven L, Habets EJJ, van den Bent MJ, Taphoorn MJB, Bromberg JEC (2018) Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncol 19(8):e407\u2013e418. https:\/\/doi.org\/10.1016\/S1470-2045(18)30356-5","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07216-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:06:28Z","timestamp":1791673588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07216-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":127,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7216"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07216-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"434"}}